Fraction of Lsr-autoinduced cells decreases as the standard deviation of the parameters <i>K</i>_<i>synth</i> or <i>V</i>_<i>ydgG</i> increases. by David N. Quan (142171)

Fig 7 - by Henning Carstens (13132801)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Chronic exposure of human PAC to nicotine decreases carrier-mediated [³H] thiamin uptake. by Padmanabhan Srinivasan (481324)

T37A mutation protects M1 protein of BJ/3/99 virus from degradation directed by PKG and increases the viral replication. by Chenxi Wang (284364)

Subjects:

5-AZA blocks dexamethasone (DEX)-induced down-regulation of cyclin D2 in the heart. by Maresha S. Gay (693467)

M1-37T protein is degraded in a lysosome-independent manner, and its ubiquitination is not through K48 linkage. by Chenxi Wang (284364)

Subjects:

M1 protein harboring T37 is susceptible to ubiquitination at K187. by Chenxi Wang (284364)

Subjects:

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

The replacement of T37 with A37 protects M1 protein from degradation directed by PKG. by Chenxi Wang (284364)

Subjects:

K187 is responsible for the M1 stability directed by PKG. by Chenxi Wang (284364)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

NCM treatment diminishes the activity and expression Complexes IV and V of the respiratory chain, which is associated with increased hepatic CYP2E1 protein levels. by Ryan J. Mailloux (50825)

Subjects: “…mitochondrial ATP synthase subunit ATP 5A…”

Loss of T37 phosphorylation protects M1 protein from degradation directed by PKG. by Chenxi Wang (284364)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Identification of lysine (K) residues that mediate M1 stability. by Chenxi Wang (284364)

Subjects: